Inozyme Pharma (INZY) Stock Chart & Stock Price History $2.81 +0.12 (+4.46%) (As of 11/22/2024 ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Inozyme Pharma Stock Price Performance 5 Day Performance-2.43%1 Month Performance-42.65%3 Month Performance-47.96%6 Month Performance-38.38%Year-To-Date Performance-34.04%1 Year Performance-24.05% Receive INZY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> INZY Stock Chart for Saturday, November, 23, 2024 INZY Chart by TradingView Inozyme Pharma Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization11/22/2024$2.69$2.81+4.46%$2.85$2.65403,766 shs$172.81 million11/21/2024$2.79$2.69-3.58%$2.80$2.61371,356 shs$172.81 million11/20/2024$2.81$2.79-0.71%$2.88$2.69393,295 shs$179.23 million11/19/2024$2.88$2.81-2.43%$2.95$2.75652,722 shs$180.51 million11/18/2024$3.13$2.88-7.84%$3.21$2.87438,277 shs$185.01 million11/15/2024$3.43$3.13-8.89%$3.48$3.08473,793 shs$200.75 million Get the Latest News and Ratings for INZY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. 11/14/2024$3.55$3.43-3.38%$3.60$3.41321,211 shs$220.34 million11/13/2024$3.76$3.55-5.59%$3.82$3.50284,586 shs$228.05 million11/12/2024$4.00$3.76-6.00%$3.99$3.69257,843 shs$241.54 million11/11/2024$4.02$4.00-0.50%$4.09$3.96243,491 shs$256.96 million11/08/2024$4.10$4.02-1.95%$4.13$3.99322,995 shs$252.18 million11/07/2024$4.23$4.10-3.07%$4.37$4.10517,110 shs$257.19 million11/06/2024$4.07$4.23+3.93%$4.45$4.20630,419 shs$265.37 million11/05/2024$4.42$4.07-7.92%$4.46$4.02417,795 shs$255.31 million11/04/2024$4.36$4.42+1.38%$4.74$4.37233,931 shs$277.27 million11/01/2024$4.29$4.36+1.63%$4.42$4.21261,924 shs$273.50 million10/31/2024$4.54$4.29-5.51%$4.56$4.28262,655 shs$269.13 million10/30/2024$4.62$4.54-1.73%$4.70$4.50171,003 shs$284.81 million10/29/2024$4.78$4.62-3.35%$4.78$4.52243,179 shs$289.83 million10/28/2024$4.79$4.78-0.21%$4.90$4.73242,706 shs$299.85 million10/25/2024$4.91$4.79-2.44%$5.11$4.77189,802 shs$296.29 million10/24/2024$4.90$4.91+0.20%$5.16$4.78486,030 shs$303.71 million10/23/2024$5.11$4.90-4.11%$5.13$4.81257,420 shs$303.09 million10/22/2024$5.28$5.11-3.22%$5.28$5.01267,306 shs$316.08 million Related Companies Eagle Pharmaceuticals Stock Price Chart Foghorn Therapeutics Stock Price Chart Entrada Therapeutics Stock Price Chart Tectonic Therapeutic Stock Price Chart Arbutus Biopharma Stock Price Chart AnaptysBio Stock Price Chart Phathom Pharmaceuticals Stock Price Chart ORIC Pharmaceuticals Stock Price Chart Exscientia Stock Price Chart CorMedix Stock Price Chart Receive INZY Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:INZY) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inozyme Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
